Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clin...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2013/389537 |
id |
doaj-240c6e8e9c2345e7bda76abb172229ff |
---|---|
record_format |
Article |
spelling |
doaj-240c6e8e9c2345e7bda76abb172229ff2020-11-24T22:10:53ZengHindawi LimitedBioMed Research International2314-61332314-61412013-01-01201310.1155/2013/389537389537Role of the Microbiota and Antibiotics in Primary Sclerosing CholangitisJames H. Tabibian0Jayant A. Talwalkar1Keith D. Lindor2Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Sreet SW, Rochester, MN 55905, USADivision of Gastroenterology and Hepatology, Mayo Clinic, 200 First Sreet SW, Rochester, MN 55905, USAExecutive Vice Provost & Dean, College of Health Solutions, Arizona State University, 550 North 3rd Street, Phoenix, AZ 85004, USAPrimary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness.http://dx.doi.org/10.1155/2013/389537 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
James H. Tabibian Jayant A. Talwalkar Keith D. Lindor |
spellingShingle |
James H. Tabibian Jayant A. Talwalkar Keith D. Lindor Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis BioMed Research International |
author_facet |
James H. Tabibian Jayant A. Talwalkar Keith D. Lindor |
author_sort |
James H. Tabibian |
title |
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis |
title_short |
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis |
title_full |
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis |
title_fullStr |
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis |
title_full_unstemmed |
Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis |
title_sort |
role of the microbiota and antibiotics in primary sclerosing cholangitis |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2013-01-01 |
description |
Primary sclerosing cholangitis (PSC) is an idiopathic, progressive, cholestatic liver disease with considerable morbidity and mortality and no established pharmacotherapy. In addition to the long-recognized association between PSC and inflammatory bowel disease, several lines of preclinical and clinical evidence implicate the microbiota in the etiopathogenesis of PSC. Here we provide a concise review of these data which, taken together, support further investigation of the role of the microbiota and antibiotics in PSC as potential avenues toward elucidating safe and effective pharmacotherapy for patients afflicted by this illness. |
url |
http://dx.doi.org/10.1155/2013/389537 |
work_keys_str_mv |
AT jameshtabibian roleofthemicrobiotaandantibioticsinprimarysclerosingcholangitis AT jayantatalwalkar roleofthemicrobiotaandantibioticsinprimarysclerosingcholangitis AT keithdlindor roleofthemicrobiotaandantibioticsinprimarysclerosingcholangitis |
_version_ |
1725806501350604800 |